Literature DB >> 26179666

Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice.

A K Oestreich1, S M Carleton2, X Yao3, B A Gentry4, C E Raw2, M Brown5, F M Pfeiffer6, Y Wang3, C L Phillips7,8.   

Abstract

UNLABELLED: Mice with osteogenesis imperfecta (+/oim), a disorder of bone fragility, were bred to mice with muscle over growth to test whether increasing muscle mass genetically would improve bone quality and strength. The results demonstrate that femora from mice carrying both mutations have greater mechanical integrity than their +/oim littermates.
INTRODUCTION: Osteogenesis imperfecta is a heritable connective tissue disorder due primarily to mutations in the type I collagen genes resulting in skeletal deformity and fragility. Currently, there is no cure, and therapeutic strategies encompass the use of antiresorptive pharmaceuticals and surgical bracing, with limited success and significant potential for adverse effects. Bone, a mechanosensing organ, can respond to high mechanical loads by increasing new bone formation and altering bone geometry to withstand increased forces. Skeletal muscle is a major source of physiological loading on bone, and bone strength is proportional to muscle mass.
METHODS: To test the hypothesis that congenic increases in muscle mass in the osteogenesis imperfecta murine model mouse (oim) will improve their compromised bone quality and strength, heterozygous (+/oim) mice were bred to mice deficient in myostatin (+/mstn), a negative regulator of muscle growth. The resulting adult offspring were evaluated for hindlimb muscle mass, and bone microarchitecture, physiochemistry, and biomechanical integrity.
RESULTS: +/oim mice deficient in myostatin (+/mstn +/oim) were generated and demonstrated that myostatin deficiency increased body weight, muscle mass, and biomechanical strength in +/mstn +/oim mice as compared to +/oim mice. Additionally, myostatin deficiency altered the physiochemical properties of the +/oim bone but did not alter bone remodeling.
CONCLUSIONS: Myostatin deficiency partially improved the reduced femoral bone biomechanical strength of adult +/oim mice by increasing muscle mass with concomitant improvements in bone microarchitecture and physiochemical properties.

Entities:  

Keywords:  Biomechanics; Bone; Myostatin; Osteogenesis imperfecta; Raman spectroscopy; Skeletal muscle

Mesh:

Substances:

Year:  2015        PMID: 26179666      PMCID: PMC8018583          DOI: 10.1007/s00198-015-3226-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  47 in total

1.  Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury.

Authors:  Mark W Hamrick; Phonepasong Arounleut; Ethan Kellum; Matthew Cain; David Immel; Li-Fang Liang
Journal:  J Trauma       Date:  2010-09

2.  Myostatin regulates proliferation and extracellular matrix mRNA expression in NIH3T3 fibroblasts.

Authors:  Yoshinao Z Hosaka; Mika Ishibashi; Jun-Ichi Wakamatsu; Masato Uehara; Takanori Nishimura
Journal:  Biomed Res       Date:  2012-12       Impact factor: 1.203

3.  Exercise and mechanical loading increase periosteal bone formation and whole bone strength in C57BL/6J mice but not in C3H/Hej mice.

Authors:  Y Kodama; Y Umemura; S Nagasawa; W G Beamer; L R Donahue; C R Rosen; D J Baylink; J R Farley
Journal:  Calcif Tissue Int       Date:  2000-04       Impact factor: 4.333

4.  Immunolocalization of myostatin (GDF-8) following musculoskeletal injury and the effects of exogenous myostatin on muscle and bone healing.

Authors:  Moataz Elkasrawy; David Immel; Xuejun Wen; Xiaoyan Liu; Li-Fang Liang; Mark W Hamrick
Journal:  J Histochem Cytochem       Date:  2012-01       Impact factor: 2.479

5.  Heterozygous oim mice exhibit a mild form of osteogenesis imperfecta.

Authors:  J Saban; M A Zussman; R Havey; A G Patwardhan; G B Schneider; D King
Journal:  Bone       Date:  1996-12       Impact factor: 4.398

6.  Skeletal muscle weakness in osteogenesis imperfecta mice.

Authors:  Bettina A Gentry; J Andries Ferreira; Amanda J McCambridge; Marybeth Brown; Charlotte L Phillips
Journal:  Matrix Biol       Date:  2010-07-06       Impact factor: 11.583

7.  Characterisation of connective tissue from the hypertrophic skeletal muscle of myostatin null mice.

Authors:  Mohamed I Elashry; Henry Collins-Hooper; Sakthivel Vaiyapuri; Ketan Patel
Journal:  J Anat       Date:  2012-03-30       Impact factor: 2.610

8.  Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading.

Authors:  M W Hamrick; X Shi; W Zhang; C Pennington; H Thakore; M Haque; B Kang; C M Isales; S Fulzele; K H Wenger
Journal:  Bone       Date:  2007-02-23       Impact factor: 4.398

Review 9.  Myostatin (GDF-8) as a key factor linking muscle mass and bone structure.

Authors:  M N Elkasrawy; M W Hamrick
Journal:  J Musculoskelet Neuronal Interact       Date:  2010-03       Impact factor: 2.041

10.  Gender-dependence of bone structure and properties in adult osteogenesis imperfecta murine model.

Authors:  Xiaomei Yao; Stephanie M Carleton; Arin D Kettle; Jennifer Melander; Charlotte L Phillips; Yong Wang
Journal:  Ann Biomed Eng       Date:  2013-03-28       Impact factor: 3.934

View more
  12 in total

1.  Decreasing maternal myostatin programs adult offspring bone strength in a mouse model of osteogenesis imperfecta.

Authors:  Arin K Oestreich; William M Kamp; Marcus G McCray; Stephanie M Carleton; Natalia Karasseva; Kristin L Lenz; Youngjae Jeong; Salah A Daghlas; Xiaomei Yao; Yong Wang; Ferris M Pfeiffer; Mark R Ellersieck; Laura C Schulz; Charlotte L Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-07       Impact factor: 11.205

2.  Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.

Authors:  Youngjae Jeong; Salah A Daghlas; Yixia Xie; Molly A Hulbert; Ferris M Pfeiffer; Mark R Dallas; Catherine L Omosule; R Scott Pearsall; Sarah L Dallas; Charlotte L Phillips
Journal:  J Bone Miner Res       Date:  2018-06-22       Impact factor: 6.741

3.  Administration of an activin receptor IIB ligand trap protects male juvenile rhesus macaques from simian immunodeficiency virus-associated bone loss.

Authors:  Wen Guo; Karol M Pencina; Karyn O'Connell; Monty Montano; Liming Peng; Susan Westmoreland; Julie Glowacki; Shalender Bhasin
Journal:  Bone       Date:  2017-01-26       Impact factor: 4.398

4.  Muscle contraction induces osteogenic levels of cortical bone strain despite muscle weakness in a mouse model of Osteogenesis Imperfecta.

Authors:  Alycia G Berman; Jason M Organ; Matthew R Allen; Joseph M Wallace
Journal:  Bone       Date:  2019-12-02       Impact factor: 4.398

Review 5.  Muscle-Bone Interactions in Pediatric Bone Diseases.

Authors:  Louis-Nicolas Veilleux; Frank Rauch
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

Review 6.  Deciphering Myostatin's Regulatory, Metabolic, and Developmental Influence in Skeletal Diseases.

Authors:  Catherine L Omosule; Charlotte L Phillips
Journal:  Front Genet       Date:  2021-03-29       Impact factor: 4.599

7.  Impact of Genetic and Pharmacologic Inhibition of Myostatin in a Murine Model of Osteogenesis Imperfecta.

Authors:  Catherine L Omosule; Victoria L Gremminger; Ashley M Aguillard; Youngjae Jeong; Emily N Harrelson; Lawrence Miloscio; Jason Mastaitis; Ashique Rafique; Sandra Kleiner; Ferris M Pfeiffer; Anqing Zhang; Laura C Schulz; Charlotte L Phillips
Journal:  J Bone Miner Res       Date:  2020-12-18       Impact factor: 6.741

8.  Leprdb/+ Dams Protect Wild-type Male Offspring Bone Strength from the Detrimental Effects of a High-Fat Diet.

Authors:  Arin K Oestreich; Anthony Onuzuriuke; Xiaomei Yao; Omonseigho Talton; Yong Wang; Ferris M Pfeiffer; Laura C Schulz; Charlotte L Phillips
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 5.051

Review 9.  Muscle abnormalities in osteogenesis imperfecta.

Authors:  L N Veilleux; P Trejo; F Rauch
Journal:  J Musculoskelet Neuronal Interact       Date:  2017-06-01       Impact factor: 2.041

10.  Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy.

Authors:  Kimberly K Long; Karen M O'Shea; Ramzi J Khairallah; Kelly Howell; Sergey Paushkin; Karen S Chen; Shaun M Cote; Micah T Webster; Joseph P Stains; Erin Treece; Alan Buckler; Adriana Donovan
Journal:  Hum Mol Genet       Date:  2019-04-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.